Orasis Raises $13 Million to Replace Reading Glasses with Eye Drops


The Israel-based company develops eye drops intended to alleviate farsightedness caused by aging

Clinical-stage eye drop company Orasis Pharmaceuticals Ltd. has raised $13 million in series B, the company announced Tuesday.

The round was led by California-based ophthalmology-focused Visionary Ventures, with participation from investors including from Sequoia Capital, SBI Japan-Israel Innovation Ventures, and New York-based LifeSci Venture Partners. Following the investment, Visionary Ventures' Jeffry Weinhuff and SBI's Masafuyu Tanaka will join Orasis' board of directors.

Privately-held Orasis develops an eye drop treatment for symptoms of presbyopia, the loss of the ability to focus on close objects due to loss of lens elasticity, mostly as a result of aging. In addition to creating problems with performing tasks such as reading, farsightedness can also strain the eyes and cause headaches. Founded in 2015 by a team of ophthalmology and optometry researchers, Orasis is based in Herzliya, a northern suburb of Tel Aviv.

The company states its eye drops have the potential to eliminate the need for reading glasses in patients with presbyopia.


Maverick Ventures Israel, 26 Nachmani Street, Tel Aviv, Israel 

© 2019 by Ventures Mavericks